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Current therapies for the Lesch-Nyhan Syndrome (OMIM: 300322) are off-label and experimental, often leading to
inconsistent outcomes. We here report the effects of an intrathecal baclofen therapy, carried out at the Scientific
Institute Eugenio Medea (Lecco, Italy), on three patients who no longer received benefit from previous therapies.
This treatment, as expected, ameliorated the motor symptoms and, unexpectedly, it also improved behavioural
components. This result may involve a functional interaction between baclofen and dopamine, complemented by
an anxiolytic effect. Our observations provide the rationale for the use of intrathecal baclofen administration in the
therapy of the Lesch-Nyhan Syndrome.
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Introduction
The Lesch-Nyhan Syndrome [1] (LN) (OMIM: 300322)
involves dystonia, ballism, and self-injurious and aggressive
behaviours. Although LN is severely disabling, no thera-
peutic standard can yet be indicated and treatment pro-
ceeds on the basis of isolated observations. Many therapies
for LN, both pharmacological (antispastic drugs, antipsy-
chotics, anti-parkinsonian drugs, dietary supplements) and
cellular (enzyme replacement and stem cell therapies), are
currently experimented, with inconsistent results [2]. We
report on three patients with a genetic diagnosis of clas-
sical LN, who were referred to the Scientific Institute
Eugenio Medea (Lecco, Italy) for rehabilitation. They
were treated with intrathecal baclofen (ITB) and showed
an improvement regarding both dystonia and patho-
logical behaviours.
Patients and methods
Patient 1 was 19 years old at referral. During motor devel-
opment, he never achieved head control, did not crawl or* Correspondence: emilio.clementi@unimi.it
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unless otherwise stated.walk; instead, he developed bilateral clubfoot and phasic
extensor hypertonia of the upper limbs, with dystonia and
ballism. His pathological behaviour involved very severe
self-injury and involuntary aggression, by punching and
biting. The patient constantly wore whole-body restraints
in order to contain these exacerbations. Patient 2 was re-
ferred at 39 years of age. He never achieved head control,
but crawled and walked until 9, when severe dystonia and
ballism of the limbs began. He displayed severe finger bit-
ing and required permanent finger protection. Patient 3
was 20 years old at referral. He never achieved head con-
trol, crawled scantly and never walked. He developed
strong retropulsive reactions, with dystonia involving neck
and limbs, and ballism of the arms. By punching, he in-
jured himself and attacked others. Patients were weaned
off their previous therapies (Table 1) and subsequently im-
planted with the intrathecal drug delivery device Syn-
chromed II - 20 ml (Medtronic, Minneapolis, MN, USA).
Individual ITB dosages were up titrated to achieve a satis-
factory effect on dystonia.Results
Dystonia was controlled with ITB dosages of 270 to
550 μg per day. ITB improved the quality of sleep for all
patients, as expected. This happened in the absence of
serious adverse reactions; patient 3 only experiencedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients’ previous pharmacological therapies
Patient Remote therapeutic history Previous therapy before ITB placement
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reaching the stable ITB dosage, ballism was abolished
and aggression and self-injurious behaviours ceased, thus
allowing the removal of protective restraints (details in
Tables 2 and 3). The beneficial effects of ITB therapy at
unchanged dosages persisted throughout the follow up
period (5 to 16 months).
Discussion
Currently, treatment approaches for LN are experimen-
tal, as therapeutic targets are not fully elucidated [4,5].
Dysregulation of dopaminergic pathways may be the
cause of self-injurious behaviours in LN patients [6] and
anatomical/physiological alterations were recently dem-
onstrated in specific brain regions [7]. Impaired dopa-
mine signalling during cerebral development could lead
to the compensatory hypersensitivity of dopamine recep-
tors, especially of the D1 subtype: this prevents the suc-
cess of either dopaminergic drugs (which increase
symptoms [8]) and antipsychotics (which do not target D1
receptors). The dopaminergic and GABAergic systems areconnected at multiple levels and GABA has a prominent
influence on dopamine release in the mesolimbic and
nigrostriatal circuits [9]. Moreover, baclofen may serve as
a functional antagonist of dopamine: GABAB receptors
are coupled to G proteins that inhibit adenylyl cyclase ac-
tivity, while D1 dopamine receptors activate it. Baclofen
may also have a direct anxiolytic effect [10] that could
complement its activity on the dopaminergic balance and
be useful for behavioural improvement. The use of baclo-
fen and ITB for LN patients is not uncommon, a popula-
tion study reported on ten users of oral baclofen and one
of ITB, although it did not discuss therapeutic efficacy [2].
Good results of ITB therapy were also previously observed
in two patients, although only little information was re-
ported [11]. In order to compare available data, debate
should be fostered between clinicians with different expe-
riences on baclofen treatment in LN. Our cases further
support the use of ITB in patients with LN within a multi-
targeted therapy that may ameliorate both motor and be-
havioural symptoms. ITB may represent a viable therapy
for LN patients, especially in light of the severity of this
Table 3 Detailed scores from patients’ UDRS scales
Patient Before ITB After ITB
1
Duration factor: 3 Duration factor: 0
Motor severity factor: eyes and upper face: 1, lower face: 3, jaw and
tongue: 2, larynx: 0, neck: 2, shoulder and proximal arm. 2, distal arm
and hand (including elbow): 3, pelvis and proximal leg: 3, distal leg and
foot (including knee): 2, trunk: 1.
Motor severity factor: eyes and upper face: 2, lower face: 1, jaw and
tongue: 1, larynx: 0, neck: 1, shoulder and proximal arm 0, distal arm and
hand (including elbow): 0, pelvis and proximal leg: 0, distal leg and foot
(including knee): 0, trunk: 0.
Total = 22 Total = 5
2
Duration factor: 4 Duration factor: 0.5
Motor severity factor: eyes and upper face: 1, lower face: 4, jaw and
tongue: 3, larynx: 0, neck: 4, shoulder and proximal arm. 4, distal arm
and hand (including elbow): 4, pelvis and proximal leg: 4, distal leg and
foot (including knee): 4, trunk: 1.
Motor severity factor: eyes and upper face: 1, lower face: 0, jaw and
tongue: 1, larynx: 1, neck: 1, shoulder and proximal arm. 0, distal arm
and hand (including elbow): 0, pelvis and proximal leg: 1, distal leg and
foot (including knee): 0, trunk: 0.
Total = 23 Total = 6.5
3
Duration factor: 4 Duration factor: 1
Motor severity factor: eyes and upper face: 1, lower face: 4, jaw and
tongue: 4, larynx: 0, neck: 3, shoulder and proximal arm. 3, distal arm
and hand (including elbow): 2, pelvis and proximal leg: 3, distal leg and
foot (including knee): 4, trunk: 0.
Motor severity factor: eyes and upper face: 1, lower face: 1, jaw and
tongue: 2, larynx: 0, neck: 1, shoulder and proximal arm: 1, distal arm
and hand (including elbow): 1, pelvis and proximal leg: 2, distal leg and
foot (including knee): 1, trunk: 0.
Total = 38 Total = 11
Table 2 Patients’ symptoms before and after treatment with intrathecal baclofen
Patient 1 2 3
Before ITB Dystonia: 22 23 38
UDRS totala
Aggression Yes No Yes
Self-injuryb:
Mouth/lip biting 2-3 2 1-2
Finger biting 10 20 3-4
Punching 10 0 2-3
Restraint Permanent whole body restraint Permanent finger protection None
Sleepc:
Awakenings 7-8 5-6 5-6
Sleep hours 2 4 4
Date of ITB implantation and age (years) 29/04/2013 – 19 28/02/2014 – 39 19/03/2014 – 20
ITB dosage and follow-up duration (months) 380 μg /day – 16 270 μg /day – 6 550 μg /day – 5
After ITB Dystonia: 5 6.5 11
UDRS totala
Aggression No No No
Self-injuryb:
Mouth/lip biting 0-1 0 0
Finger biting 3 5 0
Punching 0 0 0
Restraint Occasional, right arm None None
Sleepc:
Awakenings 1-2 1 0
Sleep hours 5 6 5
Notes Improved verbal communication - Persistent moderate nausea,
daytime drowsiness
Legend: a) Dystonia was scored using the UDRS scale [3]. Detailed scores are available in Table 3. b) Self-injury was scored by counting the daily episodes of different
self-injurious behaviours, following interviews with caregivers. c) Quality of sleep was scored counting the number of awakenings per night and the average hours of
uninterrupted sleep, following interviews with caregivers.
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http://www.ojrd.com/content/9/1/208disease and of the lower comparative risk of severe side ef-
fects. Nevertheless, catheters for ITB administration may
become infected, leading to removal in spite of partial ITB
efficacy [12]. The risks of infection may be avoided by oral
administration of baclofen, which is in general safe, apart
from rare cases of hepatic toxicity [13]. We conclude that
baclofen is potentially useful as a therapy for LN, but that
additional studies should be conducted, in order to
properly assess its efficacy. Both intrathecal and oral ad-
ministration routes should be investigated, with system-
atic measurements and long follow-up periods.
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